“It is a good transaction and a win-win deal from the outside for both. Sun will get access to Ranbaxy’s products and an entry into Japan (through Daiichi) which is a difficult market. Daiichi was not able to manage Ranbaxy’s regulatory problems. Sun would be able to manage this, as it has done in the past. The deal though may not trigger more local consolidations. We have done many in the past, and there has also been Torrent’s buy of Elder Pharma’s operations. There will continue to be individual transactions, but this will not be a trend”

Ajay Piramal

Chairman, Piramal Enterprises